title: Paclitaxel-based regimens as first-line treatment in advanced gastric cancer.
abstract: The aim of this study was to evaluate the efficacy and safety of paclitaxel-based regimens as first-line treatments in advanced gastric cancer. We reviewed 397 previously untreated patients with advanced gastric cancer, who non-randomly received one of three paclitaxel-based regimens: paclitaxel plus fluorouracil/leucovorin (PF), paclitaxel plus oxaliplatin (PO), and paclitaxel plus oxaliplatin plus fluorouracil/leucovorin (POF) between January 2003 and December 2010. The PF, PO, and POF response rates were 47.13, 52.08, and 63.78%, respectively. Overall survivals (OS) were 11.2, 11.7, and 11.7 months, respectively. Progression-free survivals (PFS) were 6.6, 7.2, and 7.1 months, respectively. Leucopenia was higher on the triplet regimen than the doublet regimens. The paclitaxel-based regimens appeared to be effective in patients with advanced gastric cancer. The triplet regimen produced a higher response rate than either doublet regimen with more side effects, while survivals were similar among all three treatments.
authors.forename: Zengqing
authors.initials: Z
authors.lastname: Guo
authors.forename: Xiaojie
authors.initials: X
authors.lastname: Wang
authors.forename: Rongbo
authors.initials: R
authors.lastname: Lin
authors.forename: Ling
authors.initials: L
authors.lastname: Chen
authors.forename: Nanfeng
authors.initials: N
authors.lastname: Fan
authors.forename: Yu
authors.initials: Y
authors.lastname: Chen
authors.forename: Jinyuan
authors.initials: J
authors.lastname: Lin
authors.forename: Jiami
authors.initials: J
authors.lastname: Yu
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002173:Cancer Care Facilities; D002681:China / Q000453:epidemiology; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004943:Esophagogastric Junction / Q000187:drug effects / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D007970:Leukopenia / Q000139:chemically induced / Q000453:epidemiology; D008297:Male; D008499:Medical Records; D008875:Middle Aged; D060787:Neoplasm Grading; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015995:Prevalence; D012189:Retrospective Studies; D013270:Stomach / Q000187:drug effects / Q000473:pathology; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016019:Survival Analysis
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel
keywords: Advanced gastric cancer,; Chemotherapy,; Fluorouracil,; Oxaliplatin,; Paclitaxel